Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

This study has been completed.
BIAFFIN GmbH & Co. KG (Biomolecular Interaction Analyses)
i3 Statprobe
Information provided by (Responsible Party):
GE Healthcare Identifier:
First received: June 9, 2009
Last updated: June 6, 2014
Last verified: June 2014

Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET acquisitions, and tumors demonstrate detectable levels of 18F uptake on PET.

Condition Intervention Phase
Solid Tumors
High Grade Gliomas
Lung Cancer
Head and Neck Cancer
Renal Cell Carcinoma
Breast Cancer
Drug: Fluciclatide Injection
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.

Resource links provided by NLM:

Further study details as provided by GE Healthcare:

Primary Outcome Measures:
  • Test Image and Retest Image Reproducibility of Fluciclatide Injection ([18F]AH111585) Uptake by Solid Tumors Following Intravenous Administration of AH111585 (18F) Injection Via PET Imaging. [ Time Frame: Forty minutes, 65 minutes and 90 minutes post Fluciclatide administration. ] [ Designated as safety issue: No ]
    Mean relative differences of Standardized uptake value (SUV) following intravenous administration of AH111585 (F18) Injection between the two PET imaging sessions.

Secondary Outcome Measures:
  • The Safety of Greater Than or Equal to 2 Administrations, Each of a Maximum of 370MBq, Fluciclatide Injection (AH111585 (18F) Injection) in Subjects With Solid Primary or Metastatic Tumors. [ Time Frame: Up to 8 weeks post contrast administration. ] [ Designated as safety issue: Yes ]
    Safety was monitored throughout the duration of the subject's participation.

Enrollment: 70
Study Start Date: June 2009
Study Completion Date: October 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fluciclatide Injection
Fluciclatide Injection
Drug: Fluciclatide Injection
Fluciclatide Injection (AH111585 (18F) Injection)
Other Names:
  • Fluciclatide
  • AH111585 (18F) Injection


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject has been diagnosed with at least one solid primary or metastatic tumor greater than 2.0 cm in diameter, including but not limited to NSCLC, RCC, GBM, melanoma, sarcoma, breast and H&N cancers.
  • The subject has received clinical routine imaging diagnostic work-up within 8 weeks prior to the first [18F]AH111585 PET scan.
  • The subject has a clinically acceptable (as judged by the investigator) physical examination at screening and is capable of self-care.

Exclusion Criteria:

  • The subject has known hyper- or hypo-coagulation syndromes.
  • The subject has received chemotherapy within 3 weeks, or received radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to the first [18F]AH111585 PET scan.
  • The subject is scheduled to undergo chemotherapy, radiotherapy, surgery or any other treatment against cancer between the first and second [18F]AH111585 PET scans.
  • The subject is scheduled to undergo biopsy for the target tumour between the first and second [18F]AH111585 PET scans.
  • The subject has intra-hepatic tumour(s) only.
  • For the immuno-histochemistry group, the subject's target tumour has been biopsied less than or equal to 1 week prior to the first [18F]AH111585 PET scan.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00918281

United States, New Jersey
101 Carnegie Center
Princeton, New Jersey, United States, 08540
Sponsors and Collaborators
GE Healthcare
BIAFFIN GmbH & Co. KG (Biomolecular Interaction Analyses)
i3 Statprobe
Principal Investigator: Jeffrey Winick, Ph.D. GE Healthcare
  More Information

No publications provided

Responsible Party: GE Healthcare Identifier: NCT00918281     History of Changes
Other Study ID Numbers: GE-135-004
Study First Received: June 9, 2009
Results First Received: October 23, 2013
Last Updated: June 6, 2014
Health Authority: United States: Food and Drug Administration
India: Drugs Controller General of India
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Breast Neoplasms
Carcinoma, Renal Cell
Head and Neck Neoplasms
Lung Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases
Urologic Diseases
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Neoplasms, Connective and Soft Tissue processed this record on September 14, 2014